TNF and COVID-19: A case report described that a 60-year-old man who received subcutaneous etanercept treatment for spondyloarthritis prior to SARS-CoV-2 infection presented no signs of respiratory failure and progressive deterioration and showed rapid recovery from COVID-19.269 Infliximab is another clinically approved TNFα blocker.